U.S. Regenerative Medicine Market Size to Hit USD 102.23 Billion by 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Regenerative Medicine Market

5.1. COVID-19 Landscape: Regenerative Medicine Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. U.S. Regenerative Medicine Market, By Product

8.1. U.S. Regenerative Medicine Market, by Product

8.1.1. Gene Therapies

8.1.1.1. Market Revenue and Forecast

8.1.2. Cell Therapies

8.1.2.1. Market Revenue and Forecast

8.1.3. Tissue-Engineering

8.1.3.1. Market Revenue and Forecast

8.1.4. Small Molecules & Biologics

8.1.4.1. Market Revenue and Forecast

Chapter 9. U.S. Regenerative Medicine Market, By Material

9.1. U.S. Regenerative Medicine Market, by Material

9.1.1. Synthetic material

9.1.1.1. Market Revenue and Forecast

9.1.2. Biologically derived material

9.1.2.1. Market Revenue and Forecast

9.1.3. Genetically Engineered Material

9.1.3.1. Market Revenue and Forecast

9.1.4. Pharmaceutical

9.1.4.1. Market Revenue and Forecast

Chapter 10. U.S. Regenerative Medicine Market, By Application

10.1. U.S. Regenerative Medicine Market, by Application

10.1.1. Wound Care

10.1.1.1. Market Revenue and Forecast

10.1.2. Musculoskeletal

10.1.2.1. Market Revenue and Forecast

10.1.3. Ophthalmology

10.1.3.1. Market Revenue and Forecast

10.1.4. Oncology

10.1.4.1. Market Revenue and Forecast

10.1.5. Cardiovascular

10.1.5.1. Market Revenue and Forecast

10.1.6. Dermatology

10.1.6.1. Market Revenue and Forecast

10.1.7. Neurology

10.1.7.1. Market Revenue and Forecast

10.1.8. Others

10.1.8.1. Market Revenue and Forecast

Chapter 11. U.S. Regenerative Medicine Market, By End User

11.1. U.S. Regenerative Medicine Market, by End User

11.1.1. Hospitals & Clinics

11.1.1.1. Market Revenue and Forecast

11.1.2. Commercial Industries

11.1.2.1. Market Revenue and Forecast

11.1.3. Government & Academic Research Institutes

11.1.3.1. Market Revenue and Forecast

Chapter 12. U.S. Regenerative Medicine Market, Regional Estimates and Trend Forecast

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Product

12.1.5.2. Market Revenue and Forecast, by Material

12.1.5.3. Market Revenue and Forecast, by Application

12.1.5.4. Market Revenue and Forecast, by End User

Chapter 13. Company Profiles

13.1. Integra LifeSciences Corporation

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Aspect Biosystems

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Amgen, Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Medtronic plc

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. AstraZeneca

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Novartis AG

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Smith & Nephew plc

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. MiMedx Group

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Shenzhen SibionoGeneTech Co., Ltd.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Baxter

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The U.S. regenerative medicine market size is expected to increase from USD 19.77 billion in 2025 to USD 102.23 billion by 2035.

Answer : The U.S. regenerative medicine market is expected to grow at a compound annual growth rate (CAGR) of around 17.86% from 2026 to 2035.

Answer : The major players in the U.S. regenerative medicine market include Integra LifeSciences Corporation (U.S.), Bristol-Myers Squibb Company (U.S.), American CryoStem Corporation (U.S.), Kite (Gilead Sciences, Inc.) (U.S.), Allergan Aesthetics (AbbVie Inc.) (U.S.), MIMEDX Group, Inc. (U.S.), Stryker (U.S.), AlloSource (U.S.), and Bluebird bio, Inc. (U.S.).

Answer : The driving factors of the U.S. regenerative medicine market are the increasing prevalence of chronic and degenerative diseases, rising investment in stem cell and gene therapy research, and growing adoption of advanced tissue engineering and personalized treatment approaches.